脂质代谢重编程:乳腺癌进展和瘤微环境中的未知英雄
Mengting Wan1, Shuaikang Pan1,2, Benjie Shan1
1Department of Medical Oncology, The First Affiliated Hospital of USTC, Division of Life Science and Medicine, University of Science and Technology of China, Hefei, China.
Molecular cancer
|March 2, 2025
概括
乳腺癌 (BC) 细胞对脂质代谢进行重新编程,以便在富含脂质的环境中生长和生存. 向脂质代谢为BC提供了有前途的治疗策略,影响瘤进展和微环境.
科学领域:
- 在瘤学瘤学.
- 代谢途径 代谢途径
- 癌症生物学 癌症生物学
背景情况:
- 异常的脂质代谢是癌症的一个关键特征.
- 乳腺癌 (BC) 在富含脂质的微环境中发展,并依赖于改变的脂质代谢.
- 脂质代谢显著影响BC进展和瘤微环境.
研究的目的:
- 审查脂质代谢在乳腺癌进展和瘤微环境中的作用.
- 探索BC细胞和瘤微环境之间的脂质信号传递.
- 要总结针对BC中的脂质代谢的治疗策略.
主要方法:
- 关于乳腺癌中的脂质代谢的文献综述.
- 分析瘤微环境中的脂质信号.
- 评估治疗点,包括代谢过程,转录因子和免疫治疗.
主要成果:
- 脂质代谢重编程对于BC进展和患者预后至关重要.
- 脂质作为信号分子,在瘤微环境中的相互作用中介.
- 准脂质代谢为BC提供了可行的治疗途径.
结论:
- 了解脂质代谢对于BC治疗至关重要.
- 脂向疗法显示出潜力,但需要进一步的临床研究.
- 未来的研究应该利用时空多态学来实现先进的脂质向策略.
相关概念视频
The Tumor Microenvironment
6.5K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K


